Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air®

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Bousquet, Jean
• dc.contributor.author Antó i Boqué, Josep Maria
• dc.contributor.author Zuberbier, Torsten
• dc.date.accessioned 2024-11-22T11:36:53Z
• dc.date.available 2024-11-22T11:36:53Z
• dc.date.issued 2024
• dc.description.abstract Patient-reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person-centred care. This paper reviews studies performed on PROMs for assessing AR and asthma control, in particular VAS scales that are included in the app MASK-air® (Mobile Airways Sentinel networK) for asthma and rhinitis. VASs were initially developed on paper and pencil and tested for their criterion validity, cut-offs and responsiveness. Then, a multicentric, multinational, double-blind, placebo-controlled, randomised control trial (DB-PC-RCT) using an electronic VAS form was carried out. Finally, with the development of MASK-air® in 2015, previously validated VAS questions were adapted to the digital format and further methodologic evaluations were performed. VAS for asthma, rhinitis, conjunctivitis, work and EQ-5D are included in the app. Additionally, two control-medication scores for allergic symptoms of asthma (e-DASTHMA) were validated for their criterion validity, cut-offs and responsiveness.
• dc.description.sponsorship This work has received funding from ARIA and the European Union's Horizon Europe research and innovation programme under Grant Agreement No 101057131, Climate Action To Advance HeaLthY Societies in Europe (CATALYSE). MASK-air® has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA and H2020), and educational grants from Mylan-Viatris, ALK, GSK, Novartis, Stallergènes-Greer and Uriach. Jean Bousquet developed the concept of the paper, was involved in all reported studies and wrote the paper. Bernardo Sousa-Pinto, Josep M. Anto, Joao A. Fonseca, Torsten Zuberbier had a major role in MASK-air studies. Anna Bedbrook and Wienczyslawa Czarlewski had a major role in all studies. Ignacio J. Ansotegui, Karl-C. Bergmann, Fulvio Braido, Luisa Brussino, Lorenzo Cecchi, Claudia Chaves Loureiro, Alvaro A. Cruz, Philippe Devillier, Alessandro Fiocchi, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Ludger Klimek, Marek Kulus, Piotr Kuna, Maciej Kupczyk, Violeta Kvedariene, Desiree E. Larenas-Linnemann, Gilles Louis, Renaud Louis, Michael Makris, Mario Morais-Almeida, Marek Niedoszytko, Ken Ohta, Markus Ollert, Nikolaos Papadopoulos, Vincenzo Patella, Benoit Pétré, Oliver Pfaar, Francesca Puggioni, Santiago Quirce, Frederico S. Regateiro, Nicolas Roche, Philip W. Rouadi, Boleslaw Samolinski, Joaquin Sastre, Florence Schleich, Nicola Scichilone, Luis Taborda-Barata, Sanna Toppila-Salmi, Arunas Valiulis, Ilgim Vardaloglu Koyuncu, Maria Teresa Ventura, 0 Arzu Yorgancioglu participated to the studies and the discussion of the paper. All authors agreed with the contents of the paper and participated in the writing of the study.
• dc.format.mimetype application/pdf
• dc.identifier.citation Bousquet J, Sousa-Pinto B, Anto JM, Bedbrook A, Czarlewski W, Ansotegui IJ, et al. Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air®. Clin Transl Allergy. 2024 Sep;14(9):e12390. DOI: 10.1002/clt2.12390
• dc.identifier.doi http://dx.doi.org/10.1002/clt2.12390
• dc.identifier.issn 2045-7022
• dc.identifier.uri http://hdl.handle.net/10230/68782
• dc.language.iso eng
• dc.publisher Wiley
• dc.relation.ispartof Clin Transl Allergy. 2024 Sep;14(9):e12390
• dc.relation.projectID info:eu-repo/grantAgreement/EC/HE/101057131
• dc.rights © 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword EQ‐5D
• dc.subject.keyword Asthma
• dc.subject.keyword Digital health
• dc.subject.keyword Rhinitis
• dc.subject.keyword Visual analogue scale
• dc.title Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air®
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion